Medical/Pharmaceuticals
Zocdoc Launches The AI-Informed Patient Report, Revealing How Patient Use of AI Is Reshaping the Patient-Provider Relationship
New findings highlight rising—yet hidden—patient use of AI and surprisingly optimistic providers, pointing to an emerging "triangle of care" NEW YORK, March 24, 2026 /PRNewswire/ -- Zocdoc, the healthcare access infrastructure connecting patients to great care, today releasedThe AI-Informed Pati...
2026-03-24 21:00
2045
ZEISS expands ophthalmic workflow portfolio in Canada with enhanced diagnostic, visualization and therapeutic solutions for precision eye care
* Expanded treatment and visualization capabilities within posterior care workflows: ICGA for ZEISS CLARUS 700 offers FA + ICG simultaneous capture to help support clinical assessment and streamline the diagnostic process; ZEISS VISULAS green, now available with ZEISS SLT, offers dependable ret...
2026-03-24 21:00
2877
HKeyBio Launches HKEY-NHP-onChip™ 1.1: World's First NHP In Vitro Model for Autoimmune and Allergic Diseases
The integrated organ-on-chip platform offers 10–100x cost efficiency and 80% reduction in animal use, bridging the gap between preclinical NHP research and human clinical success. SUZHOU, China, SAN FRANCISCO and BOSTON, March 24, 2026 /PRNewswire/ -- HKeyBio, a global leading CRO specializing in...
2026-03-24 20:30
2274
Discovery Life Sciences and Mindpeak Partner to Bring AI Precision to Cancer Biomarker Testing in Global Clinical Trials
New alliance takes aim at inconsistent biomarker interpretation across pathologists, a persistent challenge in drug development HUNTSVILLE, Ala. and HAMBURG, Germany, March 24, 2026 /PRNewswire/ -- Inconsistent biomarker interpretation across pathologists remains one of the more stubborn challen...
2026-03-24 20:00
2283
Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study
Collaboration supports IND-enabling development and a planned Phase 1/2a first-in-human clinical study in type 1 diabetes CARY, N.C. and NEW YORK, March 24, 2026 /PRNewswire/ -- Continuity Biosciences and Breakthrough T1D, the leading global type 1 diabetes (T1D) advocacy organization, today ann...
2026-03-24 20:00
1753
WuXi Biologics Reports Record 2025 Annual Results
* Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY * IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps) * EBITDA rose 38.1% YoY and IFRS net profit increased 45.3% YoY; ...
2026-03-24 19:44
2226
Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women's Health
CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced a strategic research collaboration with ASKA Pharmaceutical Co., Ltd. ("ASKA"), a specialized p...
2026-03-24 18:29
2117
GCCL Showcases RSV FRNT Research and Integrated Bioanalytical Capabilities at World Vaccine Congress 2026
YONGIN, South Korea, March 24, 2026 /PRNewswire/ -- GCCL Co., Ltd. (GCCL), a global clinical trial laboratory services provider, announced that it will attend World Vaccine Congress 2026 (WVC 2026), taking place from March 30 to April 2 in Washington, D.C., where it will operate an exhibition boo...
2026-03-24 17:35
2001
Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC
CHENGDU, China, March 24, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that the Investigational New Drug (IND) application for SKB103, its self-developed novel bispecific antibody-drug conjugate with combined T...
2026-03-24 17:24
1966
DualityBio (9606.HK) Announces 2025 Annual Results
HONG KONG, March 24, 2026 /PRNewswire/ -- Duality Biotherapeutics, Inc. (Hong Kong Stock Exchange Code: 09606.HK, hereinafter referred to as "DualityBio" or the "Company"), a leading global clinical-stage innovative biopharmaceutical company, today announced its first annual results since listing...
2026-03-24 15:55
3077
Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)
Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung cancer SINGAPORE, March 24, 2026 /PRNewswire/ -- Prestige Biopharma today announced positive topline results from its Phase 3 SAMSON-II study ev...
2026-03-24 11:32
2850
KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF
* Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase. * R&D Expenses was approximately RMB1319.68 million. * Loss for the period was RMB381.97 million, adjusted annual loss[1] was approxim...
2026-03-24 10:44
2326
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer
SUZHOU, China, March 24, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in the Phase III clinical study (KN026-007) of HER2 bispecific antibody Anbenitamab (KN026) in combination with albumin-bound docetaxel (HB1801) and chemothe...
2026-03-24 09:32
2327
The Phase 3 Registration STAR Study of Efdamrofusp Alfa (IBI302) Met its Primary Endpoint, Making it the First Self-developed Extended-interval Treatment for nAMD in China
* 73% of participants achieved Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to Q20W. SAN FRANCISCO and SUZHOU, China, March 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharma...
2026-03-24 08:00
2387
Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis
CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS SYDNEY, March 24, 2026 /PRNewswire/ -- Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, today announced dosing of the first participant in its Phas...
2026-03-24 05:30
2461
Ordering Both ESR and CRP Lab Tests Could Save Hospitals Millions Per Year -- New Study Challenges Notion the Tests are Interchangeable
Peer-reviewed economic analysis finds a combined ESR + CRP testing strategy
reduces misdiagnoses and delivers net cost savings compared to CRP alone
SMITHFIELD, R.I., March 24, 2026 /PRNewswire/ --
2026-03-24 04:32
2571
Sisram Medical Reports Solid Growth in 2025
Solid growth driven by strong performance in international markets, with the injectables business accelerating rapidly DAXXIFY shows promising results from initial commercialization in China, with expansion plans underway HONG KONG, March 23, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company"...
2026-03-23 22:56
3491
WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate CRDMO
* Revenue increased by 46.7% YoY to RMB 5,944 million * Gross profit surged by 72.5% YoY to RMB 2,139 million, with its margin of 36.0%, a 5.4 percentage points increase compared to 2024 * Adjusted net profit increased by 69.9% YoY to RMB 1,559 million, with its margin of 26.2%, a 3.6 percen...
2026-03-23 21:15
4117
NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, March 23, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begi...
2026-03-23 21:00
4291
Insilico Medicine Launches PandaClaw: Empowering Biologists with Agentic AI for Therapeutic Discovery
CAMBRIDGE, Mass., March 23, 2026 /PRNewswire/ -- Insilico Medicine
("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven
drug discovery company, today announced the launch ofPandaClaw, a
transformative new feature of thePandaOmics
2026-03-23 20:30
3073
Week's Top Stories
Most Reposted
Visa Working Capital Index: Asia Pacific CFOs Call for Flexible, Digital Finance Solutions
[Picked up by 308 media titles]
2026-03-24 14:00HOY Unveils a Powerhouse Line-up of Talent for its Bold New Chapter
[Picked up by 306 media titles]
2026-03-20 09:36
Indonesia's P2P Lending Grows 25%, JULO Strengthens Credit Quality
[Picked up by 300 media titles]
2026-03-26 18:18
MetaOptics progresses on its strategic growth and leadership transition initiatives
[Picked up by 283 media titles]
2026-03-20 08:15ART CENTRAL COMMENCES DISCOVERY-LED ELEVENTH EDITION
[Picked up by 277 media titles]
2026-03-25 16:51
Most Read
Everbright Environment Announces 2025 Annual Results
2026-03-20 23:14
7964
Ten Pao Group Announces 2025 Annual Results
2026-03-20 23:35
7750
FiEE, Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results
2026-03-21 04:05
7725
U Power Limited Announces Closing of $6.0 Million Public Offering
2026-03-21 02:40
7257